Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

61. Menopause Chapter 8: Prescription Therapies

Menopause Chapter 8: Prescription Therapies Chapter 8: Prescription Therapies | | | | Chapter 8: Prescription Therapies > > > CONTRACEPTIVES Key Points Despite a decline in fertility, women of older reproductive age who do not wish to conceive should use effective contraception until 1 year after the final menstrual period. Long-acting reversible contraceptive methods, which include the copper intrauterine device (IUD), the two levonorgestrel intrauterine systems, and the etonogestrel subdermal (...) with a uterus. Systemic HT and low-dose vaginal ET are very effective treatments for moderate to severe symptoms of vulvar and vaginal atrophy (vaginal dryness, dyspareunia, and atrophic vaginitis). The estrogen agonist/antagonist ospemifene is a new oral agent approved for this indication. Recommendations for Clinical Care The lowest dose of HT should be used for the shortest duration needed to manage menopausal symptoms. Individualization is important in the decision to use HT and should incorporate

The North American Menopause Society2014

62. Menopause Chapter 7: Nonprescription Options

Menopause Chapter 7: Nonprescription Options Chapter 7: Nonprescription Options | | | | Chapter 7: Nonprescription Options > > > GOVERNMENT REGULATIONS FOR DIETARY SUPPLEMENTS Key Points Regulation of prescription drugs as well as over-the-counter (OTC) drugs by FDA is explicit and defined by federal statutes contained in the 1938 Federal Food, Drug, and Cosmetic Act (FDCA). This Act is continually being amended and updated. New prescription drug marketing approval and postmarketing safety (...) ; randomized clinical trials of calcium in combination with vitamin D demonstrate a role in fracture prevention. The main dietary sources of calcium are dairy products (including milk, cheese, and yogurt), which provide an average of 70% of the total calcium intake in midlife and older women. Calcium requirements for skeletal maintenance in women fluctuate throughout life but increase after menopause due to increased bone resorption and decreased intestinal calcium absorption, both of which are associated with decreased

The North American Menopause Society2014

63. Menopause Chapter 6: Complementary and Alternative Medicine

Menopause Chapter 6: Complementary and Alternative Medicine Chapter 6: Complementary and Alternative Medicine | | | | Chapter 6: Complementary and Alternative Medicine > > > INTEGRATIVE MEDICINE Key Points A National Institutes of Health survey found that 36% of Americans use some form of complementary and alternative medicine (CAM). When megavitamin use and prayer for health reasons are included in the definition of CAM, the percentage rises to 62%. Increased dietary soy (legumes, soy, tofu (...) ), isoflavone products, and other forms of phytoestrogens reduce menopause symptoms, although clinical trials demonstrate benefit generally similar to that of placebo. Acupuncture reduces hot flashes and improves sleep patterns in postmenopausal women, although clinical trials demonstrate benefit generally similar to that of sham acupuncture. Regular consumption of soy isoflavones in the diet may offer breast cancer protection if exposure occurs during breast development. Soy isoflavones also may inhibit

The North American Menopause Society2014

64. Menopause Chapter 5: Clinical Evaluation and Counseling

Menopause Chapter 5: Clinical Evaluation and Counseling Chapter 5: Clinical Evaluation and Counseling | | | | Chapter 5: Clinical Evaluation and Counseling > > > HISTORY AND PHYSICAL EXAM Key Points The health evaluation at the time of the menopause transition should be tailored to the individual woman based on her medical, social, and family history, as well as on her symptoms and quality-of-life goals. Sexual and psychological histories are an important part of the assessment of women during (...) the menopause transition. The evidence supporting various aspects of the physical exam, including the clinical breast exam and bimanual pelvic exam, is limited and contradictory. Recommendations for Clinical Care A thorough history and focused physical exam can guide clinicians and their patients in managing the symptoms of the menopause transition and providing guidance to support enhanced health for women as they age. (Level II) The evaluation and counseling of a midlife woman should be individualized

The North American Menopause Society2014

65. Menopause Chapter 4: Disease Risk

Menopause Chapter 4: Disease Risk Chapter 4: Disease Risk | | | | Chapter 4: Disease Risk > > > CARDIOVASCULAR HEALTH Key Points Cardiovascular disease (CVD) is the leading cause of death in women worldwide. Major risk factors for CVD in women include age, hypertension, dyslipidemia, diabetes mellitus (DM), family history of premature CVD, smoking, sedentary lifestyle, and poor diet. Novel risk factors for CVD include a history of a pregnancy complicated by preeclampsia, gestational diabetes (...) , or hypertension. Hormonal changes associated with menopause can result in an accelerated increase in low-density lipoprotein cholesterol (LDL-C) in the year following menopause. Recommendations for Clinical Care All women should be encouraged to reduce their risk for CVD, including heart attack and stroke, by engaging in regular exercise, consuming a healthy diet, achieving a normal body weight, and not smoking. Healthcare providers should evaluate all women for CVD risk using the American

The North American Menopause Society2014

66. Menopause Chapter 3: Clinical Issues

Menopause Chapter 3: Clinical Issues Chapter 3: Clinical Issues | | | | Chapter 3: Clinical Issues > > > DECLINE IN FERTILITY Key Points Fertility declines with increasing age, notably after age 35 years, or approximately 15 years before menopause. Age-related declines in fertility have been confirmed in epidemiologic studies as well as by the observation of declining pregnancy rates with advancing age in cycles of donor insemination and in vitro fertilization (IVF). Advanced maternal age (≥35 (...) . (Level II) In older women undergoing oocyte-donation IVF, single-embryo transfer should be strongly considered because of the risks associated with multiple births. (Level II) Women of advancing age considering donor-oocyte IVF should be counseled about parenting issues and health concerns specific to their age and the age and health of their partner. (Level II) UTERINE BLEEDING Key Points Approximately 90% of women experience 4 to 8 years of menstrual cycle changes before natural menopause, which

The North American Menopause Society2014

67. Menopause Chapter 2: Midlife Body Changes

Menopause Chapter 2: Midlife Body Changes Chapter 2: Midlife Body Changes | | | | Chapter 2: Midlife Body Changes > > > VULVOVAGINAL CHANGES Key Points Postmenopausal estrogen loss and aging accompanied by physiologic, vascular, neurologic, and histologic changes may result in vulvovaginal symptoms, including irritation, burning, itching, vaginal discharge, postcoital bleeding, and dyspareunia. Genitourinary syndrome of menopause (GSM), a syndrome that encompasses symptomatic vulvovaginal (...) atrophy (VVA), may have a significant impact on the quality of life of midlife women, with effects on sexual function and interpersonal relationships. Women of any age with low estrogen levels, including women with primary ovarian insufficiency, premature menopause, hypothalamic amenorrhea, or hyperprolactinemia; during lactation; or after treatment with gonadotropin-releasing hormone (GnRH) agonists/antagonists or aromatase inhibitors, may experience symptoms of GSM/VVA. The presentation, diagnosis

The North American Menopause Society2014

68. Chapter 1: Menopause

Chapter 1: Menopause Chapter 1: Menopause | | | | Chapter 1: Menopause > > > OVERVIEW OF MENOPAUSE Key Points Menopause is a normal physiologic event, defined as the final menstrual period (FMP) and reflecting loss of ovarian follicular function. Spontaneous or natural menopause is recognized retrospectively after 12 months of amenorrhea. It occurs at an average age of 52 years, but the age of natural menopause can vary widely from 40 to 58 years. Induced menopause refers to the cessation (...) of menstruation that occurs after either bilateral oophorectomy or iatrogenic ablation of ovarian function (eg, by chemotherapy or pelvic radiation). The Stages of Reproductive Aging Workshop (STRAW) established a nomenclature and a staging system for the female reproductive aging continuum in 2001, which was revised in 2011 with the STRAW + 10 staging system. According to STRAW + 10, the term menopause transition refers to the span of time when menstrual cycle and endocrine changes occur, beginning

The North American Menopause Society2014

70. Quantitative study?other: In menopausal women physical activity and taking dietary supplements may protect against coronary artery disease

Quantitative study?other: In menopausal women physical activity and taking dietary supplements may protect against coronary artery disease In menopausal women physical activity and taking dietary supplements may protect against coronary artery disease | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In menopausal women physical activity and taking dietary supplements may protect against coronary artery disease Article Text Nursing issues Quantitative study—other In menopausal women physical activity and taking dietary supplements may protect against

Evidence-Based Nursing (Requires free registration)2014

71. Systematic review and meta-analysis: Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms

Systematic review and meta-analysis: Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms Article Text Therapeutics Systematic review and meta-analysis Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms Katherine M Newton Statistics from Altmetric.com No Altmetric data

Evidence-Based Medicine (Requires free registration)2014

74. Salivary hormone testing for menopausal women

Salivary hormone testing for menopausal women Salivary hormone testing for menopausal women Salivary hormone testing for menopausal women Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Salivary hormone testing for menopausal women. Lansdale: HAYES, Inc.. Directory Publication. 2013 Authors' conclusions Salivary hormone testing (SHT) is used to measure levels (...) of hormones, including estrogens, progestogens, androgens, and cortisol. Compared with hormone testing in blood, salivary hormone testing is noninvasive and saliva can be collected by patients at home. Salivary hormone testing is often recommended for women who receive hormone replacement therapy, especially women who receive compounded hormone preparations. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Female; Hormones; Humans; Menopause

Health Technology Assessment (HTA) Database.2013

75. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. IMPORTANCE: Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention. OBJECTIVE: To report a comprehensive, integrated overview of findings from the 2 Women's Health Initiative (WHI) hormone therapy trials with extended postintervention follow-up. DESIGN (...) in both trials. CONCLUSIONS AND RELEVANCE: Menopausal hormone therapy has a complex pattern of risks and benefits. Findings from the intervention and extended postintervention follow-up of the 2 WHI hormone therapy trials do not support use of this therapy for chronic disease prevention, although it is appropriate for symptom management in some women. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00000611 .

JAMA2013 Full Text: Link to full Text with Trip Pro

76. Bioidentical hormone replacement therapy for menopausal symptoms

Bioidentical hormone replacement therapy for menopausal symptoms Bioidentical hormone replacement therapy for menopausal symptoms Bioidentical hormone replacement therapy for menopausal symptoms Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bioidentical hormone replacement therapy for menopausal symptoms. Lansdale: HAYES, Inc.. Directory Publication. 2013 (...) Authors' conclusions Bioidentical hormone replacement therapy (BHRT) includes both "natural", compounded hormones obtained from compounding pharmacies and Food and Drug Administration-approved hormones that are identical to endogenous hormones. BHRT is used to treat the symptoms of menopause, including: vasomotor symptoms, urogenital symptoms, and bone loss. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Hormone Replacement Therapys

Health Technology Assessment (HTA) Database.2013

77. Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women

Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women UTCAT2545, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women Clinical Question In postmenopausal women can the morphology of the mandibular inferior cortex be used as a screening (...) postmenopausal women (Group A) and 157 Post Menopausal women with histories of hysterectomy, oophorectomy, or estrogen use (Group B). Subjects had a diagnostic performances of panoramic measurements, Bone Mineral Density (BMD) at the lumber Spine (L2-L4) was measured by Dual –Energy X-ray Absorptiometry In vivo study Clinical trial Key results Dual Energy X ray Absorptiometry (DXA) of the Lumbar Spines (Bone Mineral Density) is the Gold Standard for Diagnosing Osteoporosis. Study group was categorized into 3

UTHSCSA Dental School CAT Library2013

79. Systematic review: Hormone therapy not recommended for chronic disease prevention in menopausal women

Systematic review: Hormone therapy not recommended for chronic disease prevention in menopausal women Hormone therapy not recommended for chronic disease prevention in menopausal women | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Hormone therapy not recommended for chronic disease prevention in menopausal women Article Text Prevention Systematic review Hormone therapy not recommended for chronic disease prevention in menopausal women Nanette K Wenger Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Nelson HD

Evidence-Based Medicine (Requires free registration)2013

80. Osphena (ospemifene) - To treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause

Osphena (ospemifene) - To treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Osphena (ospemifene) Oral Tablets Company: Shionogi Inc. Application No.: 203505 Approval Date: 2/26/2013 Persons with disabilities having problems accessing the PDF files

FDA - Drug Approval Package2013